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Survey of Health Care–Associated Infections
To the Editor: Magill et al. (March 27 issue)1 
report a 4% prevalence of health care–associated 
infections among 11,282 patients from 183 U.S. 
hospitals. In our view, an important limitation of 
the study is the ascertainment of patients. By ex-
clusively including patients who were receiving 
antimicrobial agents, the authors may have missed 
a substantial proportion of patients with health 
care–associated infections, despite their assump-
tion that the use of antimicrobial therapy is a 
highly sensitive indicator for these infections.2 
An established national prevalence surveillance 
system from the Netherlands reported that only 
71.9% of the patients with a health care–associ-
ated infection received antimicrobial drugs at the 
moment of inclusion.3 The extent of this under-
estimation probably depends on the type of in-
fection and local treatment guidelines, but it may 
be as high as one third of all cases and will, 
moreover, lead to a flawed distribution of types 
of health care–associated infections and their 
causative microorganisms. Depending on the ex-
act methods used, the distribution of types of 
health care–associated infections may further-
more be influenced by the fact that Magill and 
colleagues chose a cross-sectional approach 
(limiting the number of patients included per 
hospital).
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The Authors Reply: We agree with Voss and 
Hopman that the use of antimicrobial treatment 
to identify patients with health care–associated 
infections is a potential limitation, as we acknowl-
edged in the Supplementary Appendix (available 
with the full text of our article at NEJM.org). On 
the basis of data from our earlier surveys1 we 
believe that this approach was justified in our 
survey of 183 U.S. hospitals, in which the use of 
antimicrobial agents was prevalent. However, 
this approach may not be justified in other coun-
tries. In the Dutch national surveys and in a 
European Centre for Disease Prevention and 
Control (ECDC) prevalence survey of health care–
associated infections and the use of antimicro-
bial agents in 2011–2012,2 antimicrobial treatment 
was more narrowly defined and less prevalent 
than in our survey. Although 39.9% of the pa-
tients in our survey met antimicrobial screening 
criteria that prompted review for health care–
associated infections, just 23.3% of patients in 
Dutch hospitals in the ECDC survey would have 
met similar criteria on the basis of antimicrobial 
agents administered on the survey date.2 ECDC 
data also showed that in hospitals outside the 
Netherlands, 95.5% of health care–associated in-
fections, as compared with 81.3% of these infec-
tions in the Netherlands, occurred in patients 
who were receiving antimicrobial agents.2 The 
Centers for Disease Control and Prevention rec-
ommends that all U.S. hospitals implement anti-
microbial stewardship programs.3 As prescribing 
of antimicrobial agents improves, it will be im-
portant to reassess the sensitivity of our screen-
ing approach.
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Hyperimmune	Globulin	to	Prevent	Congenital	CMV	Infection
To the Editor: Revello et al. (April 3 issue)1 re-
port the results of a randomized, placebo-con-
trolled, phase 2 trial of hyperimmune globulin 
for the prevention of maternofetal cytomegalovi-
rus (CMV) transmission. This study was based 
on the findings of a nonrandomized 2005 study 
by Nigro et al.2 Both studies, as well as the retro-
spective observational study by Buxmann et al.,3 
used monthly administration of hyperimmune 
globulin, based on the assumption of a terminal 
elimination half-life of 22.4 days for total IgG 
antibodies.4 We reassessed the pharmacokinetic 
characteristics of the CMV-specific antibody re-
sponse5 in a volunteer pregnant woman with 
proven CMV primary infection who received in-
travenous hyperimmune globulin every 4 weeks. 
We found periodic decreases in CMV-IgG levels 
with a half-life of about 11 days, along with fluc-
tuations in epitope-specific recombinant CMV 
IgG avidity and repeated decreases in epithelial-
cell–specific neutralization capacity. These find-
ings may have an effect on clinical outcome. 
Therefore, we suggest a reanalysis of the pharma-
cokinetics of hyperimmune globulin–induced, 
compartment-specific CMV antibody and CMV 
neutralization capacity in plasma, amniotic fluid, 
and cord blood in order to redefine an optimized 
treatment schedule for the administration of 
hyperimmune globulin.
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To the Editor: Revello et al. report that the use 
of CMV-specific hyperimmune globulin did not 
significantly alter the course of congenital CMV 
infection in their study. However, several aspects 
of the study design could have led to an under-
estimation of the effect. First, hyperimmune 
globulin was discontinued when testing of amni-
otic fluid was positive for CMV. An observational 
study showed that in women with CMV-positive 
amniotic fluid, the use of hyperimmune globulin 
mitigated fetal infection.1 It is unclear whether 
these pregnancies were terminated. Second, three 
women delivered a fetus with congenital CMV 
despite negative results on amniocentesis. Al-
though an interval of 6 to 8 weeks between the 
presumed onset of maternal infection and amnio-
centesis is described for these three women, it is 
unknown whether the same interval after mater-
nal infection was respected in all patients.2 Third, 
the statistical power of the study by Revello et al. 
was based on an absolute reduction of 24 per-
centage points (a relative reduction of 60%) in 
clinical infections, as described previously.1 Al-
though the between-group difference was not 
significant, the observed absolute reduction in 
CMV infection among women receiving hyper-
immune globulin was 14 percentage points. 
However, the 95% confidence interval was −3 to 
31, which does not exclude a clinically relevant 
effect. A larger study is needed to draw definite 
conclusions.
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